Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McMaster University

$120,000.00

Uncovering novel mechanisms for resolving MASLD and liver fibrosis

EF 2025-26

Résumé
Metabolic-dysfunction associated steatotic liver disease (MASLD) is a growing epidemic in Canada, posing a major burden on public health and patient quality of life. It arises from excess fat accumulation in the liver, leading to fibrosis, liver failure, and even death. With prevalence expected to rise sharply, effective treatments are urgently needed. We currently lack treatments to reverse both MASLD and liver fibrosis but combining existing drugs such as GLP-1R agonists, the popular diabetes medication, with new liver-specific anti-fibrosis drugs may provide a much-needed solution. In mouse models of diet-induced MASLD and fibrosis, our combination treatment outperformed either drug alone, reducing fibrosis and inflammation while promoting weight loss and fat metabolism. This project seeks to define the mechanisms behind these effects through three approaches: Firstly, I will isolate cells from livers of drug-treated mice and test the mitochondria to determine whether fat is being used more efficiently as fuel compared to single-drug treatments. We will then measure how liver cells are responding to the drugs based on gene expression and compare the data collected from mice to data from humans at different stages of disease to see if our treatment is translatable. Finally, we will spatially map out the various cells of the liver directly to see how the abundance and behaviour of certain cell types is influenced by drug treatment, providing even greater insight into the treatment mechanisms. From this data, we will not only be able to determine how the combined drugs are leading to the observed outcomes, but also the mechanisms leading to these effects based on changing cellular behaviour and the location of various cell types within the liver. This project will lead to new treatments that target both MASLD and liver fibrosis simultaneously and may also uncover new drug targets for future therapeutic developments
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559326
Name
Beharry Aruun
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Uncovering novel mechanisms for resolving MASLD and liver fibrosis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Bioinformatics; Cell Biology; Computational Biology; Liver Disease; Metabolic-Associated Steatotic Liver Disease; Transcriptomics
Abstract
Metabolic-dysfunction associated steatotic liver disease (MASLD) is a growing epidemic in Canada, posing a major burden on public health and patient quality of life. It arises from excess fat accumulation in the liver, leading to fibrosis, liver failure, and even death. With prevalence expected to rise sharply, effective treatments are urgently needed. We currently lack treatments to reverse both MASLD and liver fibrosis but combining existing drugs such as GLP-1R agonists, the popular diabetes medication, with new liver-specific anti-fibrosis drugs may provide a much-needed solution. In mouse models of diet-induced MASLD and fibrosis, our combination treatment outperformed either drug alone, reducing fibrosis and inflammation while promoting weight loss and fat metabolism. This project seeks to define the mechanisms behind these effects through three approaches: Firstly, I will isolate cells from livers of drug-treated mice and test the mitochondria to determine whether fat is being used more efficiently as fuel compared to single-drug treatments. We will then measure how liver cells are responding to the drugs based on gene expression and compare the data collected from mice to data from humans at different stages of disease to see if our treatment is translatable. Finally, we will spatially map out the various cells of the liver directly to see how the abundance and behaviour of certain cell types is influenced by drug treatment, providing even greater insight into the treatment mechanisms. From this data, we will not only be able to determine how the combined drugs are leading to the observed outcomes, but also the mechanisms leading to these effects based on changing cellular behaviour and the location of various cell types within the liver. This project will lead to new treatments that target both MASLD and liver fibrosis simultaneously and may also uncover new drug targets for future therapeutic developments
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Beharry, Aruun
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~